Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + trebananib
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A dual antiangiogenic combination therapy consisting of bevacizumab, a humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), and trebananib, a novel Fc fusion protein that sequesters angiopoietin-1 and angiopoietin-2 (Ang1/Ang2). This combination targets two distinct angiogenesis pathways simultaneously to potentially enhance anti-tumor effects.
- Brand names
- Avastin
- Other names
- trebananib + bevacizumab
02
Targets
Beyond the preview
Go deeper on bevacizumab + trebananib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + trebananib.